Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P36954
UPID:
RPB9_HUMAN
Alternative names:
DNA-directed RNA polymerase II subunit I; RNA polymerase II 14.5 kDa subunit
Alternative UPACC:
P36954; B2R5J2; Q6NW05
Background:
DNA-directed RNA polymerase II subunit RPB9, also known as the 14.5 kDa subunit, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is a crucial component of RNA polymerase II, responsible for synthesizing mRNA precursors and various functional non-coding RNAs. RPB9's unique position in the polymerase II complex, part of the upper jaw, is essential for engaging the DNA template.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerase II subunit RPB9 could open doors to potential therapeutic strategies.